CHINARES PHARMA (03320) announced Kpc Pharmaceuticals,Inc.'s performance for the first half of 2025, with total operating revenue of approximately RMB 3.351 billion, down 11.68% year-on-year; net profit attributable to shareholders of listed company of approximately RMB 198 million, down 26.88% year-on-year; basic earnings per share of RMB 0.26.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.